New therapeutic strategies for castration-resistant prostate cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 3, 2011, Pages 373-383

  Tanaka, Tomoaki ^a   Nakatani, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

AR splicing variants; Bag1 l; Castration resistant prostate cancer; Caveolin; Hyaluronidase; N cadherin; Novel therapy; Patents; PCGEM 1; Target molecules

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ABIRATERONE ACETATE; AFLIBERCEPT; ANDROGEN RECEPTOR; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CABAZITAXEL; CB 7589; CUSTIRSEN; CYTOCHROME P450 17; CYTOCHROME P450 17A1; DASATINIB; DENOSUMAB; DEXAMETHASONE; DOCETAXEL; KETOCONAZOLE; LYASE INHIBITOR; ORTERONEL; PLACEBO; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; STEROID 17,20 LYASE; SUNITINIB; TASQUINIMOD; TOK 001; UNCLASSIFIED DRUG; UNINDEXED DRUG; VN 124 1; ZIBOTENTAN; ZOLEDRONIC ACID;

AMYLASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BONE METABOLISM; BONE METASTASIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HEART FAILURE; HEART INFARCTION; HORMONE ACTION; HUMAN; HYPERTENSION; HYPOKALEMIA; IMMUNE RESPONSE; LEG EDEMA; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; STROKE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALS; CARCINOMA; HUMANS; MALE; MODELS, BIOLOGICAL; ORCHIECTOMY; PROSTATIC NEOPLASMS; THERAPIES, INVESTIGATIONAL; TREATMENT FAILURE;

EID: 80052331774     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211796957793     Document Type: Review

References (106)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
4. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-8261.
5. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009; 15: 3251-3255.
6. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324: 787-790.
7. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010; 375: 1437-1446.
8. US Institute of Health, Clinical Trials. gov identifier NCT00974311. Available at http://clinicaltrials.gov (Acssesed on: Jul 10, 2010).
9. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 2004;22: 1025-1033.
10. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castrationresistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 1481-1488.
11. Attard G, Reid AH, A'Hern R Parker C, Oommen NB, Folkerd E, Messiou C, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748.
12. US Institute of Health, Clinical Trials. gov identifier NCT00638690. Available at http://clinicaltrials.gov (Acssesed on: January 8, 2011).
13. US Institute of Health, Clinical Trials. gov identifier NCT00887198. Available at http://clinicaltrials.gov (Acssesed on: Jan 8, 2011).
14. th Annual Meeting. Milan, Italy (2010).
15. Yamaoka M, Hara T, Kusaka M. Overcoming persistent dependency on androgen signaling after progression to castrationresistant prostate cancer. Clin Cancer Res 2010; 16: 4319-4324.
16. Dreicer R, Agus DB, MacVicar GR, MacLean D, Zhang T, Stadler WM, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: a phase I/II, openlabel study. American Society of Clinical Oncology Genitourinary Cancers Symposium. San Francisco, USA (2010).
17. Millennium press release. Available at: http://investor.millennium.com/ (Accessed on: January 10, 2011).
18. Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, et al. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 2008; 7: 2348-2357.
19. Schayowitz A, Sabnis G, Njar VC, Brodie AM. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther 2008; 7: 121-132.
20. Schayowitz A, Sabnis G, Goloubeva O, Njar VC, Brodie AM. Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. Br J Cancer 2010; 103: 1001-1007.
21. Tokai Pharmaceuticals press release. Available at: http://www.tokaipharma.com/ (Accessed on: January 10, 2011).
22. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12: 6296s-300s.
23. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormonerefractory prostate cancer. Cancer 2007; 110: 1959-1966.
24. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113: 2478-2487.
25. Akhavan A, McHugh KH, Guruli G, Bies RR, Zamboni WC, Strychor SA, et al. Endothelin receptor A blockade enhances taxane effects in prostate cancer in vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Neoplasia. 2006; 8: 725-732.
26. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007; 67: 3818-3826.
27. Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008; 14: 6270-6276.
28. US Institute of Health, Clinical Trials. gov identifier NCT00134056. Available at http://clinicaltrials.gov (Acssesed on: January 8, 2011).
29. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: A double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 1112-1123.
30. US Institute of Health, Clinical Trials. gov identifier NCT00626548. Available at http://clinicaltrials.gov (Acssesed on: January 8, 2011).
31. US Institute of Health, Clinical Trials. gov identifier NCT00554229. Available at http://clinicaltrials.gov (Acssesed on: January 8, 2011).
32. US Institute of Health, Clinical Trials. gov identifier NCT00617669. Available at http://clinicaltrials.gov (Acssesed on: January 8, 2011).
33. AstraZeneca press release. Available at: http://www.astrazeneca.com/ (Accessed on: January 5, 2011).
34. Narducci P, Bareggi R, Nicolin V. Receptor activator for nuclear factor kappa B ligand (RANKL) as an osteoimmune key regulator in bone physiology and pathology. Acta Histochem 2009; 17: 17.
35. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006;25: 541-549.
36. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
37. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the pre vention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
38. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R, Lipton A, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized phase II trial randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Urol 2009; 182: 509-515.
39. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-1571.
40. US Institute of Health, Clinical Trials. gov identifier NCT00321620. Available at http://clinicaltrials.gov (Acssesed on: January 9, 2011).
41. US Institute of Health, Clinical Trials. gov identifier NCT00266091. Available at http://clinicaltrials.gov (Acssesed on: Jan 9, 2011).
42. Fizazi K, Carducci MA, Smith MR, Damião R, Brown JE, Karsh L, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. American Society of Clinical Oncology Annual Meeting. Chicago, USA (2010).
43. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-1936.
44. Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, et al. Combination of bevacizumab and docetaxel in docetaxelpretreated hormone-refractory prostate cancer: A phase 2 study. Eur Urol 2008; 54: 1089-1094.
45. US Institute of Health, Clinical Trials. gov identifier NCT00110214. Available at http://clinicaltrials.gov (Acssesed on: July 10, 2010).
46. Kelly WK. CALGB90401: Bevacizumab plus docetaxel/predonisone did not increase survival in metastatic CRPC. American Society of Clinical Oncology Annual Meeting. Chicago, USA (2010).
47. Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008; 270: 229-233.
48. Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, et al. Sunitinib malate for metastatic castrationresistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21: 319-324.
49. US Institute of Health, Clinical Trials. gov identifier NCT00676650. Available at http://clinicaltrials.gov (Acssesed on: January 10, 2011).
50. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010; 28: 207-214.
51. Tew WP, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian C, et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010; 16: 358-366.
52. US Institute of Health, Clinical Trials. gov identifier NCT00519285. Available at http://clinicaltrials.gov (Acssesed on: January 10, 2011).
53. Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 2006; 66: 1768-1778.
54. Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate 2007; 67: 790-797.
55. Olsson A, Bjork A, Vallon-Christersson J, Isaacs JT, Leanderson T. Tasquinimod (ABR-215050), a quinoline-3-carboxamide antiangiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010; 9: 107.
56. Bratt O, Haggman M, Ahlgren G, Nordle O, Bjork A, Damber JE. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer 2009; 101: 1233-1240.
57. Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, et al. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC). American Society of Clinical Oncology Annual Meeting. Chicago, USA (2010).
58. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormonerefractory prostate cancer. Clin Cancer Res 2009; 15: 3540-3549.
59. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185-9189.
60. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009; 101: 263-268.
61. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7421-7428.
62. US Institute of Health, Clinical Trials. gov identifier NCT00744497. Available at http://clinicaltrials.gov (Acssesed on: January 10, 2011).
63. So A, Hadaschik B, Sowery R, Gleave M. The role of stress proteins in prostate cancer. Curr Genomics 2007; 8: 252-261.
64. Rizzi F, Bettuzzi S. Clusterin (CLU) and prostate cancer. Adv Cancer Res 2009; 105: 1-19.
65. Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010; 16: 1088-1093.
66. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 4247-4254.
67. US Institute of Health, Clinical Trials. gov identifier NCT01188187. Available at http://clinicaltrials.gov (Acssesed on: January 10, 2011).
68. US Institute of Health, Clinical Trials. gov identifier NCT01083615. Available at http://clinicaltrials.gov (Acssesed on: January 10, 2011).
69. Tudor G, Aguilera A, Halverson DO, Laing ND, Sausville EA. Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ 2000; 7: 574-586.
70. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgenindependent prostate cancer. Cancer Res 1992; 52: 6940-6944.
71. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009; 15: 3172-3176.
72. MacVicar GR, Greco A, Reeves J, Maleski J, Holmlund J, Leopold L. An open -label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and predonisone (P) in men with castrate-resistant prostate cancer (CRPC). American Society of Clinical Oncology Annual Meeting. Orlando, USA (2009).
73. US Institute of Health, Clinical Trials. gov identifier NCT00571675. Available at http://clinicaltrials.gov (Acssesed on: January 10, 2011).
74. Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 723-730.
75. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376: 1147-1154.
76. Lee JJ, Kelly WK. Epothilones: Tubulin polymerization as a novel target for prostate cancer therapy. Nat Clin Pract Oncol 2009; 6: 85-92.
77. Hussain M, Tangen CM, Lara PN, Jr., Vaishampayan UN, Petrylak DP, Colevas AD, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormonerefractory prostate cancer: A Southwest Oncology Group trial S0111. J Clin Oncol 2005; 23: 8724-8729.
78. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110: 556-563.
79. Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20: 492-497.
80. Beardsley EK, Saad F, Eigl B, Venner P, Hotte S, Winquist E, et al. A phase II study of patupilone in patients (PTS) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel. American Society of Clinical Oncology Annual Meeting. Orlando, USA (2009).
81. Latif T, Wood L, Connell C, Smith DC, Vaughn D, Lebwohl D, et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005; 23: 79-84.
82. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 2009; 27: 5431-5438.
83. De Jager RL, Roman LD, Lopatkin NA, Karlov PA, Breitz HB, Earhart RH, et al. Phase II study of picoplatin with docetaxel and predonisone in first-line treatment of castration-resistant prostate cancer (CRPC). American Society of Clinical Oncology Genitourinary Cancers Symposium. San Francisco, USA (2010).
84. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894-3903.
85. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094.
86. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-3679.
87. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
88. Northwest Biotherapeutics. Available at: http://www.nwbio.com/clinical_dcvax_prostate.php. (Accessed on: January 11, 2011).
89. DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006; 4: 1-5.
90. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007; 178: 1515-1520.
91. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59: 663-674.
92. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-1105.
93. Frost, G.I., Jiang, P., Thompson, C.B. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions. US20100003238 (2010).
94. Bharadwaj AG, Kovar JL, Loughman E, Elowsky C, Oakley GG, Simpson MA. Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol 2009; 174: 1027-1036.
95. Thompson, T. C. Methods for the treatment of neoplastic disorders with anti-caveolin agents. US7666412 (2010).
96. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, et al. The role of caveolin-1 in prostate cancer: Clinical implications. Prostate Cancer Prostatic Dis. 2010;13: 6-11.
97. Cato, A.B.C., Shatkina, L., Jehle, K., Maddalo, D. Bag-1 peptide that inhibits prostate cancer. WO2010012452 (2010).
98. Maddalo D, Neeb A, Jehle K, Shatkina L, Cato A. Heat shock proteins: Distinct peptides derived from the cochaperone Bag-1L inhibit prostate cancer cell growth. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. Boston, USA (2009).
99. Reiter, R. E. N-cadoherin: Target for cancer diagnosis and therapy. US20100119527 (2010).
100. Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE, Welen K. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr Relat Cancer 2010; 17: 469-479.
101. Qiu, Y., Guo, Z., Yang, X. Novel human androgen receptor alternative splice variants as biomarkers and therapeutic targets. US20100068802 (2010).
102. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-2313.
103. Worm, J. LNA antagonists targeting the androgen receptor. US7737125 (2010).
104. Srivastava, S., Moul, J. W, Srikantan, V., Zou, Z. Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer. US7807373 (2010).
105. Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S. Regulation of apoptosis by a prostate-specific and prostate cancerassociated noncoding gene, PCGEM1. DNA Cell Biol 2006; 25: 135-141.
106. Romanuik TL, Wang G, Morozova O, Delaney A, Marra MA, Sadar MD. LNCaP Atlas: Gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Med Genomics 2010; 3: 43.